Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 7/20 | 0.41 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886058 | 0.93 | KMT2A (0.43) | TSHRMEN1KMT2ANPSR1 | |
| SCHEMBL4886049 | 0.93 | KMT2A (0.43) | TSHRMEN1KMT2ANPSR1 | |
| SCHEMBL4602951 | 0.91 | NPSR1 (0.48) | TSHRMEN1KMT2ANPSR1 | |
| SCHEMBL4877576 | 0.91 | NPSR1 (0.48) | TSHRMEN1KMT2ANPSR1 | |
| SCHEMBL4603077 | 0.90 | TSHR (0.41) | TSHREPHX2SLC6A5TEAD1PHGDH | |
| SCHEMBL4883080 | 0.90 | TSHR (0.41) | TSHREPHX2SLC6A5TEAD1PHGDH | |
| SCHEMBL4887977 | 0.89 | TSHR (0.41) | TSHREPHX2MEN1KMT2ANPSR1 | |
| SCHEMBL4887987 | 0.89 | TSHR (0.41) | TSHREPHX2MEN1KMT2ANPSR1 | |
| SCHEMBL4884726 | 0.86 | PDF (0.45) | TSHREPHX2SLC6A5TEAD1PHGDH | |
| SCHEMBL4884713 | 0.86 | PDF (0.45) | TSHREPHX2SLC6A5TEAD1PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | KANG JAE-HOON | 2008-09-25 | — | — | US | disclosed |
| WO-2006115353-A9 | A NOVEL HYDROXAMIC ACID DERIVATIVE AS PEPTIDE DEFORMYLASE INHIBITOR AND MANUFACTURING METHOD THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | PDF, PEPD, DHPS | TSHR 3586/4885EPHX2 2553/4885SLC6A5 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.